N-Myc Proto-Oncogene Protein
"N-Myc Proto-Oncogene Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.
|N-Myc Proto-Oncogene Protein
- N-Myc Proto-Oncogene Protein
- N Myc Proto Oncogene Protein
- Proto-Oncogene Protein, N-Myc
- BHLHE37 Protein
- NMYC Protein
- Class E Basic Helix-Loop-Helix Protein 37
- Class E Basic Helix Loop Helix Protein 37
- N-Myc Protein
- N Myc Protein
- MYCN Protein
Below are MeSH descriptors whose meaning is more general than "N-Myc Proto-Oncogene Protein".
Below are MeSH descriptors whose meaning is more specific than "N-Myc Proto-Oncogene Protein".
This graph shows the total number of publications written about "N-Myc Proto-Oncogene Protein" by people in this website by year, and whether "N-Myc Proto-Oncogene Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "N-Myc Proto-Oncogene Protein" by people in Profiles.
MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 Dec; 17(13):2056-2074.
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794.
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697.
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
A conserved HH-Gli1-Mycn network regulates heart regeneration from newt to human. Nat Commun. 2018 10 12; 9(1):4237.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51.
Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018 10; 37(40):5451-5465.
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).